Pharmacokinetic-pharmacodynamic relationships for analgesics

被引:0
|
作者
Suri, A
Estes, KS
Geisslinger, G
Derendorf, H
机构
[1] NOVA SE UNIV, COLL PHARM, DEPT PHARMACEUT, FT LAUDERDALE, FL 33328 USA
[2] NOVA SE UNIV, COLL PHARM, DEPT PHARMACEUT SCI, FT LAUDERDALE, FL 33314 USA
[3] UNIV ERLANGEN NURNBERG, COLL MED, DEPT PHARMACOL, D-8520 ERLANGEN, GERMANY
关键词
analgesics; pharmacokinetics; pharmacodynamics;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A major goal of current pain research is to develop scientifically-based guidelines to optimize selection of analgesic drug doses and control pain. Numerous clinical studies have shown that the drug dose required to effectively alleviate pain is often highly variable, both between patients and between pain episodes in individual patients. This high variability makes it difficult to predict appropriate dosing regimens that will adequately control pain in the individual patient, The result is a ''trial and error'' approach to analgesic therapy. Experimental tools that measure analgesic response and drug disposition after administration of analgesics can be used to better predict the therapeutic effects of analgesics in individual patients. The approach defines factors that contribute to variability in therapeutic response, Pharmacokinetic-pharmacodynamic (PK/PD) modeling involves analysis of drug disposition data and drug efficacy data, Modeling depends on sensitive and reliable methods to quantify both pain and plasma (or other body fluid) levels of analgesic agents. Two major approaches have been used to quantify pain. The first utilizes subjective reports from patients, while the second employs physiological correlates of pain, such as evoked potentials. Results from PK/PD analysis that successfully identify a relationship between drug dose, drug concentration, and effect can be used to predict the effects of drug dose on analgesic effect in individuals. The ultimate goal is to provide patients with better pain relief by understanding variables that affect the analgesic concentration/effect relationship, This review examines the available pharmacokinetic-pharmacodynamic (PK/PD) data for selected opioid and nonopioid analgesics. Even though most analgesics are used clinically in multiple doses, the majority of PK/PD studies conducted to date evaluated single dose effects. Further studies with multiple doses are required to evaluate the validity of PK/PD relationships defined from single dose studies.
引用
收藏
页码:307 / 323
页数:17
相关论文
共 50 条
  • [21] Pharmacokinetic-pharmacodynamic modeling of doxacurium: Effect of input rate
    Zhu, YL
    Audibert, G
    Donati, F
    Varin, F
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1997, 25 (01): : 23 - 37
  • [22] PHARMACOKINETIC-PHARMACODYNAMIC AND METABOLITE MODELING WITH TOPFIT
    TANSWELL, P
    HEINZEL, G
    WEISENBERGER, H
    ROTH, W
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1995, 33 (10) : 550 - 554
  • [23] Pharmacokinetic-pharmacodynamic modeling of daurisoline and dauricine in beagle dogs
    Shi, SJ
    Chen, H
    Gu, SF
    Zeng, FD
    ACTA PHARMACOLOGICA SINICA, 2003, 24 (10) : 1011 - 1015
  • [24] Personalized pharmacotherapy in oncology: Application of pharmacokinetic-pharmacodynamic criteria
    Porta-Oltra, Begona
    Merino-Sanjuan, Matilde
    FARMACIA HOSPITALARIA, 2021, 45 : 45 - 55
  • [25] Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients
    Alhadab, Ali A.
    Ahmed, Mariam A.
    Brundage, Richard C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (04)
  • [26] Pharmacokinetic-pharmacodynamic integration of danofloxacin in the calf
    Aliabadi, FS
    Lees, P
    RESEARCH IN VETERINARY SCIENCE, 2003, 74 (03) : 247 - 259
  • [27] Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic model
    Lozano, Roberto
    Domeque, Nieves
    Apesteguia, Alberto-Fermin
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 153 - 159
  • [28] PHARMACOKINETIC-PHARMACODYNAMIC EVALUATION OF DEFLAZACORT IN COMPARISON TO METHYLPREDNISOLONE AND PREDNISOLONE
    MOLLMANN, H
    HOCHHAUS, G
    ROHATAGI, S
    BARTH, J
    DERENDORF, H
    PHARMACEUTICAL RESEARCH, 1995, 12 (07) : 1096 - 1100
  • [29] Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments
    Andrew Hooker
    Paolo Vicini
    The AAPS Journal, 7
  • [30] Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic
    Dowell, James A.
    Goldstein, Beth R.
    Buckwalter, Mary
    Stogniew, Martin
    Damle, Bharat
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09) : 1063 - 1068